Hormonal
Obesity drives systemic inflammation through adipose tissue secretion of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6), which directly contributes to cardiovascular disease risk factors including atherosclerosis, hypertension, and insulin resistance.
If you have excess body fat, especially around your midsection, your body is actively releasing inflammatory chemicals that damage your blood vessels and increase your risk of heart disease and diabetes. Losing weight, particularly through diet and exercise, reduces this inflammation and lowers your cardiovascular risk, independent of just lowering cholesterol.
Mounting evidence highlights the role of adipose tissue in the development of a systemic inflammatory state that contributes to obesity-associated vasculopathy and cardiovascular risk.
Why this rating
The paper is a comprehensive review citing numerous human epidemiological studies, animal models, and clinical trials, though it acknowledges some conflicting data for specific cytokines like TNF-alpha.
Source
Adipose Tissue, Inflammation, and Cardiovascular Disease
Anders H. Berg et al. · Circulation Research · 2005
DOI 10.1161/01.res.0000163635.62927.34
More from this paper
- Adiponectin, an adipocyte-secreted protein, has cardioprotective effects, and its levels are decreased in obesity, contributing to increased cardiovascular risk.Good
- Weight loss, achieved through various methods including diet, exercise, and surgery, significantly decreases systemic inflammation and improves cardiovascular risk markers.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →